Physical Exercise for Treatment of Mood Disorders: A Critical Review
- 955 Downloads
Purpose of the review
The purpose of this review is to critically assess the evidence for exercise as an adjunct intervention for major depressive disorder and bipolar disorder, chronic conditions characterized by frequent comorbid conditions as well as interepisodic symptoms with poor quality of life and impaired functioning. Individuals with these mood disorders are at higher risk of cardiovascular disease and premature death in part because of increased rates of obesity, inactivity, and diabetes mellitus compared to the general population. Exercise may not only mitigate the increased risk of cardiovascular disease, but could also potentially improve the long term outcomes of mood disorders.
We conducted a literature review on the impact of exercise on mood disorders and associated comorbid conditions as well as possible biological mechanisms. We found that exercise impacts both the physical health parameters of mood disorders as well as mental health outcomes. Exercise also positively impacts conditions frequently comorbid with mood disorders (i.e. anxiety, pain, and insomnia). There are multiple candidate biomarkers for exercise, with brain-derived neurotrophic factor and oxidative stress as two main promising components of exercise’s anti-depressant effect.
Exercise appears to be a promising adjunct treatment for mood disorders. We conclude with recommendations for future research of exercise as an adjunct intervention for mood disorders.
KeywordsBipolar disorder depression mood disorders exercise cardiovascular disease adjunctive intervention
Compliance with Ethical Standards
Ms. Hearing has no competing interests to report.
Ms. Chang has no competing interests to report.
Dr. Deckersbach’s research has been funded by NIH, NIMH, NARSAD, TSA, IOCDF, Tufts University, DBDAT and Otsuka Pharmaceuticals. He has received honoraria, consultation fees and/or royalties from the MGH Psychiatry Academy, BrainCells Inc., Clintara, LLC., Systems Research and Applications Corporation, Boston University, the Catalan Agency for Health Technology Assessment and Research, the National Association of Social Workers Massachusetts, the Massachusetts Medical Society, Tufts University, NIDA, NIMH, Oxford University Press, Guilford Press, and Rutledge. He has also participated in research funded by DARPA, NIH, NIMH, NIA, AHRQ, PCORI, Janssen Pharmaceuticals, The Forest Research Institute, Shire Development Inc., Medtronic, Cyberonics, Northstar, and Takeda.
Dr. Nierenberg serves as a consultant for Abbott Laboratories, Alkermes, American Psychiatric Association, Appliance Computing Inc. (Mindsite), Basliea, Brain Cells, Inc., Brandeis University, Bristol Myers Squibb, Clintara, Corcept, Dey Pharmaceuticals, Dainippon Sumitomo (now Sunovion), Eli Lilly and Company, EpiQ, L.P./Mylan Inc., Forest, Genaissance, Genentech, GlaxoSmithKline, Healthcare Global Village, Hoffman LaRoche, Infomedic, Intra-cellular Therapies, Lundbeck, Janssen Pharmaceutica, Jazz Pharmaceuticals, Medavante, Merck, Methylation Sciences, NeuroRx, Naurex, Novartis, PamLabs, Parexel, Pfizer, PGx, Health, Otsuka, Ridge Diagnostics Shire, Schering-Plough, Somerset, Sunovion, Takeda Pharmaceuticals, Targacept, and Teva; He has also consulted through the MGH Clinical Trials Network and Institute (CTNI) for Astra Zeneca, Brain Cells, Inc., Dianippon Sumitomo/Sepracor, Johnson and Johnson, Labopharm, Merck, Methylation Science, Novartis, PGx Health, Shire, Schering-Plough, Targacept and Takeda/Lundbeck Pharmaceuticals. He has received grants/research support from American Foundation for Suicide Prevention, AHRQ, Brain and Behavior Research Foundation, Bristol-Myers Squibb, Cederroth, Cephalon, Cyberonics, Elan, Eli Lilly, Forest, GlaxoSmithKline, Intra-Cellular Therapies, Janssen Pharmaceutica, Lichtwer Pharma, Marriott Foundation, Mylan, NIMH, PamLabs, PCORI, Pfizer Pharmaceuticals, Shire, Stanley Foundation, Takeda, and Wyeth-Ayerst and honoraria from Belvoir Publishing, University of Texas Southwestern Dallas, Brandeis University, Bristol-Myers Squibb, Hillside Hospital, American Drug Utilization Review, American Society for Clinical Psychopharmacology, Baystate Medical Center, Columbia University, CRICO, Dartmouth Medical School, Health New England, Harold Grinspoon Charitable Foundation, IMEDEX, International Society for Bipolar Disorder, Israel Society for Biological Psychiatry, Johns Hopkins University, MJ Consulting, New York State, Medscape, MBL Publishing, MGH Psychiatry Academy, National Association of Continuing Education, Physicians Postgraduate Press, SUNY Buffalo, University of Wisconsin, University of Pisa, University of Michigan, University of Miami, University of Wisconsin at Madison, APSARD, ISBD, SciMed, Slack Publishing and Wolters Klower Publishing, ASCP, NCDEU, Rush Medical College, Yale University School of Medicine, NNDC, Nova Southeastern University, NAMI, Institute of Medicine, CME Institute, ISCTM, World Congress on Brain Behavior and Emotion, Congress of the Hellenic Society for Basic and Clinical Pharmacology, and ADAA. Dr. Nierenberg has stock in Appliance Computing, Inc. (MindSite), Brain Cells, Inc., and Medavante. He holds copyrights for Clinical Positive Affect Scale and the MGH Structured Clinical Interview for the Montgomery Asberg Depression Scale exclusively licensed to the MGH Clinical Trials Network and Institute (CTNI).
Dr. Sylvia was a shareholder in Concordant Rater Systems and has served in the past year as a consultant for United Biosource Corporation, Clintara, Bracket, and Clinical Trials Network and Institute. Dr. Sylvia receives royalties from New Harbinger. She has received grant/research support from NIMH, PCORI, AFSP, and Takeda.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by the any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 7.Vancampfort D, Vansteelandt K, Correll CU, Mitchell AJ, De Herdt A, Sienaert P, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatr. 2013:170(3).Google Scholar
- 8.Goldstein BI, Carnethon MR, Matthews KA, McIntyre RS, Miller GE, et al. Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2015;132(10):965–86.CrossRefPubMedGoogle Scholar
- 11.Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000;61(suppl 11):1,478-41.Google Scholar
- 27.Thomson D, Alyna T, Lauder S, Gigler ME, Berk L, Singh AB, et al. A brief review of exercise, bipolar disorder, and mechanistic pathways. Front Psychol. 2015;6(147):1–10.Google Scholar
- 28.••Sylvia, LG, Salcedo S, Bernstein EE, Baek JH, Nierenberg AA, Deckersbach T. Nutrition, exercise, and wellness treatment in bipolar disorder: feasibility, acceptability and preliminary efficacy. Int J Bipolar Disord. 2013;1(24):1–7. One of very few studies using a novel exercise intervention in bipolar individuals.Google Scholar
- 29.El-Rafie MM, Khafagy GM, Gamal MG. Effect of aerobic exercise during pregnancy on antenatal depression. Int J Women's Health. 2016;8:53.Google Scholar
- 30.Siqueira CC, Valiengo LL, Carvalho AF, Santos-Silva PR, Missio G, de Sousa RT, et al. Antidepressant efficacy of adjunctive aerobic activity and associated biomarkers in major depression: a 4-week, randomized, single-blind, controlled clinical trial. PLoS ONE. 2016;11(5):e0154195.CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Fernandes G, Jennings F, Cabral MVN, Buosi ALP, Natour J. Swimming improves pain and functional capacity of patients with fibromyalgia: a randomized controlled trial. Arch Phys Med Rehabil. 2016; p. in press.Google Scholar
- 35.Mathers C, Fat DM, Boerma JT. The global burden of disease: 2004 Update. 2008: World Health Organization.Google Scholar
- 36.Ishak WW, Greenberg JM, Cohen RM. Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the individual burden of illness index for depression (IBI-D). J Affect Disord. 2013;151(1):59–65.CrossRefPubMedPubMedCentralGoogle Scholar
- 42.Gill A, Womack R, Safranek S. Does exercise alleviate symptoms of depression? Clinical Inquiries, 2010 (MU). 2010.Google Scholar
- 48.Amati F, Dubé JJ, Coen PM, Stefanovic-Racic M, Toledo FG, Goodpaster BH. Physical inactivity and obesity underlie the insulin resistance of aging. Diabetes Care, 2009. in press.Google Scholar
- 50.Ströhle A, Höfler M, Pfister H, Muller A, Hoyer J, Wittchen H, et al. Physical activity and prevalence and incidence of mental disorders in adolescents and young adults. Psychol Med. 2007;37(11):1657–66.Google Scholar
- 51.Hays AE. Effect of an acute bout of aerobic exercise on dehydroepiandrosterone sulphate (DHEAS) in clinically diagnosed bipolar subjects. 2007. University of Pittsburgh.Google Scholar
- 52.Edenfield TM. Exercise and mood: exploring the role of exercise in regulating stress reactivity in bipolar disorder. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2008. 68(8-B): p. 5566.Google Scholar
- 56.Edgar DM, Dement WC. Regularly scheduled voluntary exercise synchronizes the mouse circadian clock. Am J Phys Regul Integr Comp Phys. 1991;261(4):R928–33.Google Scholar
- 58.Solberg LC, Horton TH, Turek FW. Circadian rhythms and depression: effects of exercise in an animal model. Am J Phys Regul Integr Comp Phys. 1999;276(1):R152–61.Google Scholar
- 63.Simon NM, Otto MW, Wisniewski SR, Fossey M, Sagduyu K, Frank E, et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatr. 2004;161(12):2222–9.CrossRefPubMedGoogle Scholar
- 66.Bakish D. The patient with comorbid depression and anxiety: the unmet need. J Clin Psychiatr. 1999;60(6):20–4.Google Scholar
- 68.Physical activity reduces stress. 6/24/2016]; Available from: http://www.adaa.org/understanding-anxiety/related-illnesses/other-related-conditions/stress/physical-activity-reduces-st.
- 71.Broocks A, Bandelow B, Pekrun G, George A, Meyer T, Bartmann U, et al. Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry, 1998.Google Scholar
- 72.Szuhany KL, Smits JAJ, Asmundson GJG, Otto MW. Exercise for mood and anxiety disorders: a review of efficacy, mechanisms, and barriers. Oxford Handbooks Online; 2014. pp. 1–22.Google Scholar
- 114.Wang J-F. Defects of mitochondrial electron transport chain in bipolar disorder: implications for mood-stabilizing treatment. Can J Psychiatry-Rev Can Psychiatr. 2007;52(12):753–62.Google Scholar
- 119.Ng F, Berk M, Dean O, Busch AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol. 2008;22(6):851–76.Google Scholar
- 125.Moore DS. The developing Genome: an introduction to behavioral epigenetics. New York, NY: Oxford University Press; 2015. pp. 1–309.Google Scholar
- 127.Massart R, Mongeau R, Lanfumey L. Beyond the monoaminergic hypothesis: Philos Trans R Soc B: Biol Sci neuroplasticity and epigenetic changes in a transgenic mouse model of depression. 2012;367(1601):2485–94.Google Scholar
- 130.Garber CE, Blissmer B, Deschenes MR, Franklin B, Lamonte MJ, Lee I, et al. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc. 2011;43(7):1334–59.CrossRefPubMedGoogle Scholar